BR112023001861A2 - Composições e métodos para tratamento de doenças e distúrbios - Google Patents

Composições e métodos para tratamento de doenças e distúrbios

Info

Publication number
BR112023001861A2
BR112023001861A2 BR112023001861A BR112023001861A BR112023001861A2 BR 112023001861 A2 BR112023001861 A2 BR 112023001861A2 BR 112023001861 A BR112023001861 A BR 112023001861A BR 112023001861 A BR112023001861 A BR 112023001861A BR 112023001861 A2 BR112023001861 A2 BR 112023001861A2
Authority
BR
Brazil
Prior art keywords
disorders
diseases
methods
compositions
treatment
Prior art date
Application number
BR112023001861A
Other languages
English (en)
Inventor
Von Roemeling Reinhard
Martinez Elizabeth
Martell Robert
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of BR112023001861A2 publication Critical patent/BR112023001861A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAMENTO DE DOENÇAS E DISTÚRBIOS. A presente revelação se refere a métodos de tratamento de certas doenças e distúrbios (por exemplo, doenças e distúrbios associados à IRAK4). A presente revelação também se refere a composições farmacêuticas que compreendem compostos para tratar as doenças e distúrbios anteriormente mencionados.
BR112023001861A 2020-08-03 2021-04-30 Composições e métodos para tratamento de doenças e distúrbios BR112023001861A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060413P 2020-08-03 2020-08-03
US202063115312P 2020-11-18 2020-11-18
PCT/US2021/030192 WO2022031330A1 (en) 2020-08-03 2021-04-30 Compositions and methods for treating diseases and disorders

Publications (1)

Publication Number Publication Date
BR112023001861A2 true BR112023001861A2 (pt) 2023-03-07

Family

ID=80117618

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001861A BR112023001861A2 (pt) 2020-08-03 2021-04-30 Composições e métodos para tratamento de doenças e distúrbios

Country Status (12)

Country Link
US (1) US20230310444A1 (pt)
EP (1) EP4188368A1 (pt)
JP (1) JP2023537477A (pt)
KR (1) KR20230048358A (pt)
CN (1) CN116419752A (pt)
AU (1) AU2021321350A1 (pt)
BR (1) BR112023001861A2 (pt)
CA (1) CA3188171A1 (pt)
CU (1) CU20230009A7 (pt)
IL (1) IL300310A (pt)
MX (1) MX2023001296A (pt)
WO (1) WO2022031330A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811204RA (en) 2014-01-13 2019-01-30 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia
WO2024027750A1 (en) * 2022-08-02 2024-02-08 Beigene Switzerland Gmbh Methods of treating pulmonary hypertension using btk inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201811204RA (en) * 2014-01-13 2019-01-30 Aurigene Discovery Tech Ltd Bicyclic heterocyclyl derivatives as irak4 inhibitors
KR102633530B1 (ko) * 2017-03-31 2024-02-02 오리진 온콜로지 리미티드 혈액 장애를 치료하기 위한 화합물 및 조성물
WO2019089580A1 (en) * 2017-10-31 2019-05-09 Curis, Inc. Compounds and compositions for treating hematological disorders

Also Published As

Publication number Publication date
CA3188171A1 (en) 2022-02-10
EP4188368A1 (en) 2023-06-07
AU2021321350A1 (en) 2023-03-16
KR20230048358A (ko) 2023-04-11
WO2022031330A1 (en) 2022-02-10
US20230310444A1 (en) 2023-10-05
MX2023001296A (es) 2023-02-22
CU20230009A7 (es) 2023-09-07
CN116419752A (zh) 2023-07-11
IL300310A (en) 2023-04-01
JP2023537477A (ja) 2023-09-01

Similar Documents

Publication Publication Date Title
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
DOP2023000252A (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
BR112015022096A2 (pt) moduladores de canal de sódio para o tratamento da dor
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112012014990A2 (pt) composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição.
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
BR112023019211A2 (pt) Inibidores de inflamassoma nlrp3
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo